.png)
Improving translation in neurodegenerative diseases
This event has now finished.
Dianna Bowles Lecture Theatre, B/K/018, Biology Building, Campus West, University of York (Map)
Event details
Abstract
Neurodegenerative diseases present a profound clinical and societal challenge, with limited therapeutic options and often late-stage diagnosis. This seminar will explore a discovery-focused translational framework aimed at improving outcomes across the entire disease spectrum from individuals at risk to those with established symptoms. Central to this approach is the use of novel human tissue cohorts (both ante mortem and post mortem) and the use of improved molecular tools, particularly the use of aptamers, to refine detection, monitoring, and targeted delivery of therapeutics. I will also address strategies for promoting prevention and early intervention, emphasising how understanding the underlying molecular and cellular pathways at different disease stages can guide tailored therapeutic approaches. Integrating improved translational tools with preventive and targeted strategies offers a path toward more effective, personalised management of neurodegenerative diseases.
About the speaker
Professor Jenna Gregory
Professor Jenna Gregory studied preclinical medicine at the University of St Andrews before completing her clinical training and PhD at the University of Cambridge. She then moved to the University of Edinburgh to train as a pathologist and was appointed as a SCREDS Clinical Lecturer in 2018. After completing her specialist training in pathology, she took up a Consultant post in the Department of Pathology in Aberdeen in 2022, alongside a Senior Lecturer position, and was appointed to Clinical Chair in 2024.
Her research focuses on the molecular mechanisms underlying neurodegenerative diseases, with a particular emphasis on amyotrophic lateral sclerosis (ALS). Her laboratory investigates patient samples—both tissue and biofluids—to uncover molecular differences that may explain the variability in ALS symptoms, including differences in disease progression and cognitive involvement. The goal of her work is to identify molecular targets that could be used for diagnosis, monitoring disease progression, or ultimately, developing therapies to improve outcomes for people living with ALS.
Venue details
Wheelchair accessible
Hearing loop